<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="urn:hl7-org:v3" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="2bb2bd7b-190e-1821-e063-6294a90a5c0e"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Metronidazole Vaginal Gel, 0.75%</content>
   </title>
   <effectiveTime value="20250114"/>
   <setId root="08abacec-3b6a-43e7-bfaa-2041d87a26c7"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="080145868"/>
            <name>Saptalis Pharmaceuticals LLC</name>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="2bb2cb8e-0bce-569b-e063-6294a90a696b"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20250114"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="71656-067" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>metronidazole vaginal</name>
                        <formCode code="C42934" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="GEL"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>metronidazole</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="A2I8C7HI9T" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METHYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Z8IX2SC1OH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLPARABEN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="059QF0KO0R" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>WATER</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="HHT01ZNK31" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CARBOMER HOMOPOLYMER TYPE B (ALLYL PENTAERYTHRITOL CROSSLINKED)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7FLD91C86K" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>EDETATE DISODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="55X04QC32I" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM HYDROXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="g" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="140QMO216E" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>METRONIDAZOLE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="140QMO216E" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>METRONIDAZOLE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="70" unit="g"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43207" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TUBE, WITH APPLICATOR"/>
                              <asContent>
                                 <quantity>
                                    <numerator value="1" unit="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="71656-067-70" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20250303"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA216750" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250303"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38313" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VAGINAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_8ebe434a-4be0-4a6e-950b-58ddbe3a3206">
               <id root="2bb2bd7b-190f-1821-e063-6294a90a5c0e"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR INTRAVAGINAL USE ONLY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NOT FOR OPHTHALMIC, DERMAL, OR ORAL USE</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250114"/>
            </section>
         </component>
         <component>
            <section ID="ID_6653dcb0-8524-45d4-8cba-9bc40481148c">
               <id root="2bb2bd7b-1910-1821-e063-6294a90a5c0e"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION

 <content styleCode="italics"/>
               </title>
               <text>
                  <paragraph>Metronidazole vaginal gel is the intravaginal dosage form of the synthetic antibacterial agent, metronidazole, USP at a concentration of 0.75%. Metronidazole is a member of the imidazole class of antibacterial agents and is classified therapeutically as an antiprotozoal and antibacterial agent. Chemically, metronidazole is a 2-methyl-5-nitroimidazole-1-ethanol. It has a molecular formula of C
 
  <sub>6</sub>H
 
  <sub>9</sub>N
 
  <sub>3</sub>O
 
  <sub>3</sub>, a molecular weight of 171.2 g/mole, and has the following structure:

 </paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="ID_46caa6c4-1665-402d-83ba-b21a901595fa"/>
                  </paragraph>
                  <paragraph>Metronidazole vaginal gel is a gelled, purified water solution, containing metronidazole, USP at a concentration of 7.5 mg/g (0.75%). The gel is formulated at pH 4.0. The gel also contains carbomer homopolymer, edetate disodium, methylparaben, propylparaben, propylene glycol, and sodium hydroxide.</paragraph>
                  <paragraph>Each applicator full of 5 grams of vaginal gel contains approximately 37.5 mg of metronidazole.</paragraph>
               </text>
               <effectiveTime value="20250114"/>
               <component>
                  <observationMedia ID="ID_46caa6c4-1665-402d-83ba-b21a901595fa">
                     <text>structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="structure.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_67f76921-3216-431d-ba39-c33c44396040">
               <id root="2bb2bd7b-1911-1821-e063-6294a90a5c0e"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Normal Subjects</content>
                  </paragraph>
                  <paragraph>Following a single, intravaginal 5 g dose of metronidazole vaginal gel (equivalent to 37.5 mg of metronidazole) to 12 normal subjects, a mean maximum serum metronidazole concentration of 237 ng/mL was reported (range: 152 ng/mL to 368 ng/mL). This is approximately 2% of the mean maximum serum metronidazole concentration reported in the same subjects administered a single, oral 500 mg dose of metronidazole (mean C
 
  <sub>max</sub>= 12,785 ng/mL, range: 10,013 ng/mL to 17,400 ng/mL). These peak concentrations were obtained in 6 hours to 12 hours after dosing with metronidazole vaginal gel and 1 hour to 3 hours after dosing with oral metronidazole.

 </paragraph>
                  <paragraph>The extent of exposure [area under the curve (AUC)] of metronidazole, when administered as a single intravaginal 5 g dose of metronidazole vaginal gel (equivalent to 37.5 mg of metronidazole), was approximately 4% of the AUC of a single oral 500 mg dose of metronidazole (4,977 ng-hr/mL and approximately 125,000 ng-hr/mL, respectively).</paragraph>
                  <paragraph>Dose-adjusted comparisons of AUCs demonstrated that, on a mg to mg comparison basis, the absorption of metronidazole, when administered vaginally, was approximately half that of an equivalent oral dosage.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Patients with Bacterial Vaginosis</content>
                  </paragraph>
                  <paragraph>Following single and multiple 5 g doses of metronidazole vaginal gel to 4 patients with bacterial vaginosis, a mean maximum serum metronidazole concentration of 214 ng/mL on day 1 and 294 ng/mL (range: 228 ng/mL to 349 ng/mL) on day five were reported. Steady-state metronidazole serum concentrations following oral dosages of 400 mg to 500 mg BID have been reported to range from 6,000 ng/mL to 20,000 ng/mL.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Microbiology</content>
                  </paragraph>
                  <paragraph>The intracellular targets of action of metronidazole on anaerobes are largely unknown. The 5-nitro group of metronidazole is reduced by metabolically active anaerobes, and studies have demonstrated that the reduced form of the drug interacts with bacterial DNA. However, it is not clear whether interaction with DNA alone is an important component in the bactericidal action of metronidazole on anaerobic organisms.</paragraph>
                  <paragraph>Culture and sensitivity testing of bacteria are not routinely performed to establish the diagnosis of bacterial vaginosis. (See
 
  <content styleCode="bold">
                        <linkHtml href="#ID_c89883a3-ce1e-4896-ad52-06b6712fd165">INDICATIONS AND USAGE</linkHtml>
                     </content>.)

 </paragraph>
                  <paragraph>Standard methodology for the susceptibility testing of the potential bacterial vaginosis pathogens,
 
  <content styleCode="italics">Gardnerella vaginalis</content>
                     <content styleCode="italics">, </content>
                     <content styleCode="italics">Mobiluncus</content>spp
 
  <content styleCode="italics">.</content>, and
 
  <content styleCode="italics">Mycoplasma hominis</content>, has not been defined. Nonetheless, metronidazole is an antimicrobial agent active
 
  <content styleCode="italics">in vitro</content>against most strains of the following organisms that have been reported to be associated with bacterial vaginosis:

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Bacteroides</content>spp
 
  <content styleCode="italics">.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Gardnerella vaginalis</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Mobiluncus</content>spp
 
  <content styleCode="italics">.</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="italics">Peptostreptococcus</content>spp
 
  <content styleCode="italics">.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20250114"/>
            </section>
         </component>
         <component>
            <section ID="ID_c89883a3-ce1e-4896-ad52-06b6712fd165">
               <id root="2bb2bd7b-1912-1821-e063-6294a90a5c0e"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Metronidazole vaginal gel is indicated in the treatment of bacterial vaginosis (formerly referred to as
 
  <content styleCode="italics">Haemophilus</content>vaginitis,
 
  <content styleCode="italics">Gardnerella</content>vaginitis, nonspecific vaginitis,
 
  <content styleCode="italics">Corynebacterium</content>vaginitis, or anaerobic vaginosis).

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">NOTE</content> For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent
 
  <content styleCode="italics">Lactobacillus</content>morphology, (b) predominance of
 
  <content styleCode="italics">Gardnerella</content>morphotype, and (c) absent or few white blood cells.

 </paragraph>
                  <paragraph>Other pathogens commonly associated with vulvovaginitis, e.g.,
 
  <content styleCode="italics">Trichomonas vaginalis</content>,
 
  <content styleCode="italics">Chlamydia trachomatis</content>,
 
  <content styleCode="italics">N. gonorrhoeae</content>,
 
  <content styleCode="italics">Candida albicans</content>, and
 
  <content styleCode="italics">Herpes simplex</content>virus should be ruled out.

 </paragraph>
               </text>
               <effectiveTime value="20220328"/>
            </section>
         </component>
         <component>
            <section ID="ID_0cffb1f6-4dab-4052-89f8-282542e5eeb7">
               <id root="2bb2bd7b-1913-1821-e063-6294a90a5c0e"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Metronidazole vaginal gel is contraindicated in patients with a prior history of hypersensitivity to metronidazole, parabens, other ingredients of the formulation, or other nitroimidazole derivatives.</paragraph>
               </text>
               <effectiveTime value="20250114"/>
            </section>
         </component>
         <component>
            <section ID="ID_0912677e-4590-42cc-814c-4f7264e6572f">
               <id root="2bb2bd7b-1914-1821-e063-6294a90a5c0e"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Convulsive Seizures and Peripheral Neuropathy</content>
                  </paragraph>
                  <paragraph>Convulsive seizures and peripheral neuropathy, the latter characterized mainly by numbness or paresthesia of an extremity, have been reported in patients treated with oral or intravenous metronidazole. The appearance of abnormal neurologic signs demands the prompt discontinuation of metronidazole vaginal gel therapy. Metronidazole vaginal gel should be administered with caution to patients with central nervous system diseases.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Psychotic Reactions</content>
                  </paragraph>
                  <paragraph>Psychotic reactions have been reported in alcoholic patients who were using oral metronidazole and disulfiram concurrently. Metronidazole vaginal gel should not be administered to patients who have taken disulfiram within the last 2 weeks.</paragraph>
               </text>
               <effectiveTime value="20250114"/>
            </section>
         </component>
         <component>
            <section ID="ID_f5b46538-e8ba-40f6-a698-9815b5cea4bd">
               <id root="2bb2bd7b-1915-1821-e063-6294a90a5c0e"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <text>
                  <paragraph>Metronidazole vaginal gel affords minimal peak serum levels and systemic exposure (AUCs) of metronidazole compared to 500 mg oral metronidazole dosing. Although these lower levels of exposure are less likely to produce the common reactions seen with oral metronidazole, the possibility of these and other reactions cannot be excluded presently. Data from well-controlled trials directly comparing metronidazole administered orally to metronidazole administered vaginally are not available.</paragraph>
               </text>
               <effectiveTime value="20250114"/>
               <component>
                  <section ID="ID_ae0e9f21-e081-4fa9-9db5-a9ddc280c0a3">
                     <id root="2bb2bd7b-1916-1821-e063-6294a90a5c0e"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>Patients with severe hepatic disease metabolize metronidazole slowly. This results in the accumulation of metronidazole and its metabolites in the plasma. Accordingly, for such patients, metronidazole vaginal gel should be administered cautiously.</paragraph>
                        <paragraph>Known or previously unrecognized vaginal candidiasis may present more prominent symptoms during therapy with metronidazole vaginal gel. Approximately 6% to 10% of patients treated with metronidazole vaginal gel developed symptomatic
 
  <content styleCode="italics">Candida</content>vaginitis during or immediately after therapy.

 </paragraph>
                        <paragraph>Disulfiram-like reaction to alcohol has been reported with oral metronidazole, thus the possibility of such a reaction occurring while on metronidazole vaginal gel therapy cannot be excluded.</paragraph>
                        <paragraph>Metronidazole vaginal gel contains ingredients that may cause burning and irritation of the eye. In the event of accidental contact with the eye, rinse the eye with copious amounts of cool tap water.</paragraph>
                     </text>
                     <effectiveTime value="20250114"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_b9399d77-d0bb-408d-b167-23dc3d570544">
                     <id root="2bb2bd7b-1917-1821-e063-6294a90a5c0e"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for the Patient</title>
                     <text>
                        <paragraph>The patient should be cautioned about drinking alcohol while being treated with metronidazole vaginal gel. While blood levels are significantly lower with metronidazole vaginal gel than with usual doses of oral metronidazole, a possible interaction with alcohol cannot be excluded.</paragraph>
                        <paragraph>The patient should be instructed not to engage in vaginal intercourse during treatment with this product.</paragraph>
                     </text>
                     <effectiveTime value="20220328"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_1c602b6e-fbf5-494a-bf97-157509498f89">
                     <id root="2bb2bd7b-1918-1821-e063-6294a90a5c0e"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>Oral metronidazole has been reported to potentiate the anticoagulant effect of warfarin and other coumarin anticoagulants, resulting in a prolongation of prothrombin time. This possible drug interaction should be considered when metronidazole vaginal gel is prescribed for patients on this type of anticoagulant therapy.</paragraph>
                        <paragraph>In patients stabilized on relatively high doses of lithium, short-term oral metronidazole therapy has been associated with elevation of serum lithium levels and, in a few cases, signs of lithium toxicity.</paragraph>
                        <paragraph>Use of cimetidine with oral metronidazole may prolong the half-life and decrease plasma clearance of metronidazole.</paragraph>
                     </text>
                     <effectiveTime value="20220323"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_e6019d2c-8cc9-4813-a372-66cca19290a5">
                     <id root="2bb2bd7b-1919-1821-e063-6294a90a5c0e"/>
                     <code code="34074-5" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG &amp; OR LABORATORY TEST INTERACTIONS SECTION"/>
                     <title>Drug/Laboratory Test Interactions</title>
                     <text>
                        <paragraph>Metronidazole may interfere with certain types of determinations of serum chemistry values, such as aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT), lactate dehydrogenase (LDH), triglycerides, and glucose hexokinase. Values of zero may be observed. All of the assays in which interference has been reported involve enzymatic coupling of the assay to oxidation-reduction of nicotinamide-adenine dinucleotides (NAD + NADH). Interference is due to the similarity in absorbance peaks of NADH (340 nm) and metronidazole (322 nm) at pH 7.</paragraph>
                     </text>
                     <effectiveTime value="20220323"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_0b72449b-6713-4a6d-b65c-9321a867c20c">
                     <id root="2bb2bd7b-191a-1821-e063-6294a90a5c0e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Metronidazole has shown evidence of carcinogenic activity in a number of studies involving chronic oral administration in mice and rats. Prominent among the effects in the mouse was the promotion of pulmonary tumorigenesis. This has been observed in all six reported studies in that species, including one study in which the animals were dosed on an intermittent schedule (administration during every fourth week only). At very high dose levels (approximately 500 mg/kg/day), there was a statistically significant increase in the incidence of malignant liver tumors in males. Also, the published results of one of the mouse studies indicate an increase in the incidence of malignant lymphomas as well as pulmonary neoplasms associated with lifetime feeding of the drug. All these effects are statistically significant. Several long-term oral dosing studies in the rat have been completed. There were statistically significant increases in the incidence of various neoplasms, particularly in mammary and hepatic tumors, among female rats administered metronidazole over those noted in the concurrent female control groups. Two lifetime tumorigenicity studies in hamsters have been performed and reported to be negative.</paragraph>
                        <paragraph>These studies have not been conducted with 0.75% metronidazole vaginal gel, which would result in significantly lower systemic blood levels than those obtained with oral formulations.</paragraph>
                        <paragraph>Although metronidazole has shown mutagenic activity in a number of
 
  <content styleCode="italics">in vitro</content>assay systems, studies in mammals (
 
  <content styleCode="italics">in vivo</content>) have failed to demonstrate a potential for genetic damage.

 </paragraph>
                        <paragraph>Fertility studies have been performed in mice up to six times the recommended human oral dose (based on mg/m
 
  <sup>2</sup>) and have revealed no evidence of impaired fertility.

 </paragraph>
                     </text>
                     <effectiveTime value="20220323"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a6be4f26-1683-415d-9fe8-263e45be5e31">
                     <id root="2bb2bd7b-191b-1821-e063-6294a90a5c0e"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20220323"/>
                     <component>
                        <section ID="ID_b029456d-de05-4887-b9a4-ed5e18c87eb7">
                           <id root="2bb2bd7b-191c-1821-e063-6294a90a5c0e"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">Teratogenic Effects</content>
                           </title>
                           <effectiveTime value="20220323"/>
                           <component>
                              <section ID="ID_6f2f3f19-ae80-4e15-bfa8-8173d4213250">
                                 <id root="2bb2bd7b-191d-1821-e063-6294a90a5c0e"/>
                                 <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                                 <title/>
                                 <text>
                                    <paragraph>There has been no experience to date with the use of metronidazole vaginal gel in pregnant patients. Metronidazole crosses the placental barrier and enters the fetal circulation rapidly. No fetotoxicity or teratogenicity was observed when metronidazole was administered orally to pregnant mice at six times the recommended human dose (based on mg/m
 
  <sup>2</sup>); however, in a single small study where the drug was administered intraperitoneally, some intrauterine deaths were observed. The relationship of these findings to the drug is unknown.

 </paragraph>
                                    <paragraph>There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, and because metronidazole is a carcinogen in rodents, this drug should be used during pregnancy only if clearly needed.</paragraph>
                                 </text>
                                 <effectiveTime value="20220323"/>
                              </section>
                           </component>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_fce75a36-3b2e-4192-b172-f489cc9d614d">
                     <id root="2bb2bd7b-191e-1821-e063-6294a90a5c0e"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Specific studies of metronidazole levels in human milk following intravaginally administered metronidazole have not been performed. However, metronidazole is secreted in human milk in concentrations similar to those found in plasma following oral administration of metronidazole.</paragraph>
                        <paragraph>Because of the potential for tumorigenicity shown for metronidazole in mouse and rat studies, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.</paragraph>
                     </text>
                     <effectiveTime value="20220323"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a2c1f945-209e-4e71-a0ea-9c7b52766fe8">
                     <id root="2bb2bd7b-191f-1821-e063-6294a90a5c0e"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>Safety and effectiveness in children have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20220323"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_8a0cb3a8-4c95-4820-85e7-93839dadb4be">
               <id root="2bb2bd7b-1920-1821-e063-6294a90a5c0e"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Clinical Trials</content>
                  </paragraph>
                  <paragraph>There were no deaths or serious adverse events related to drug therapy in clinical trials involving 800 non-pregnant women who received metronidazole vaginal gel.</paragraph>
                  <paragraph>In a randomized, single-blind clinical trial of 505 non-pregnant women who received metronidazole vaginal gel once or twice a day, 2 patients (one from each regimen) discontinued therapy early due to drug-related adverse events. One patient discontinued drug because of moderate abdominal cramping and loose stools, while the other patient discontinued drug because of mild vaginal burning. These symptoms resolved after discontinuation of drug.</paragraph>
                  <paragraph>Medical events judged to be related, probably related, or possibly related to administration of metronidazole vaginal gel once or twice a day were reported for 195/505 (39%) patients. The incidence of individual adverse reactions were not significantly different between the two regimens. Unless percentages are otherwise stipulated, the incidence of individual adverse reactions listed below was less than 1%:</paragraph>
                  <paragraph>
                     <content styleCode="italics">Reproductive:</content>
                  </paragraph>
                  <paragraph>Vaginal discharge (12%),</paragraph>
                  <paragraph>Symptomatic
 
  <content styleCode="italics">Candida</content>cervicitis/vaginitis (10%),

 </paragraph>
                  <paragraph>Vulva/vaginal irritative symptoms (9%),</paragraph>
                  <paragraph>Pelvic discomfort (3%).</paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal:</content>
                  </paragraph>
                  <paragraph>Gastrointestinal discomfort (7%),</paragraph>
                  <paragraph>Nausea and/or vomiting (4%),</paragraph>
                  <paragraph>Unusual taste (2%),</paragraph>
                  <paragraph>Diarrhea/loose stools (1%),</paragraph>
                  <paragraph>Decreased appetite (1%),</paragraph>
                  <paragraph>Abdominal bloating/gas; thirsty, dry mouth.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Neurologic:</content>
                  </paragraph>
                  <paragraph>Headache (5%),</paragraph>
                  <paragraph>Dizziness (2%),</paragraph>
                  <paragraph>Depression.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Dermatologic:</content>
                  </paragraph>
                  <paragraph>Generalized itching or rash.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Other:</content>
                  </paragraph>
                  <paragraph>Unspecified cramping (1%),</paragraph>
                  <paragraph>Fatigue,</paragraph>
                  <paragraph>Darkened urine.</paragraph>
                  <paragraph>In previous clinical trials submitted for approved labeling of metronidazole vaginal gel the following was also reported:</paragraph>
                  <paragraph>
                     <content styleCode="italics">Laboratory:</content>
                  </paragraph>
                  <paragraph>Increased/decreased white blood cell counts (1.7%).</paragraph>
                  <paragraph>
                     <content styleCode="bold">Other Metronidazole Formulations</content>
                  </paragraph>
                  <paragraph>Other effects that have been reported in association with the use of
 
  <content styleCode="bold">topical (dermal)</content>formulations of metronidazole include skin irritation, transient skin erythema, and mild skin dryness and burning. None of these adverse events exceeded an incidence of 2% of patients.

 </paragraph>
                  <paragraph>Metronidazole vaginal gel affords minimal peak serum levels and systemic exposure (AUC) of metronidazole compared to 500 mg oral metronidazole dosing. Although these lower levels of exposure are less likely to produce the common reactions seen with oral metronidazole, the possibility of these and other reactions cannot be excluded presently.</paragraph>
                  <paragraph>The following adverse reactions and altered laboratory tests have been reported with the
 
  <content styleCode="bold">oral or parenteral</content>use of metronidazole:

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Cardiovascular</content>
                     <content styleCode="italics">:</content>Flattening of the T-wave may be seen in electrocardiographic tracings.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Central Nervous System</content>
                     <content styleCode="italics">:</content>(See
 
  <content styleCode="bold">
                        <linkHtml href="#ID_0912677e-4590-42cc-814c-4f7264e6572f">WARNINGS</linkHtml>
                     </content>.) Headache, dizziness, syncope, ataxia, confusion, convulsive seizures, peripheral neuropathy, vertigo, incoordination, irritability, depression, weakness, insomnia.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Gastrointestinal</content>
                     <content styleCode="italics">:</content>Abdominal discomfort, nausea, vomiting, diarrhea, an unpleasant metallic taste, anorexia, epigastric distress, abdominal cramping, constipation, "furry" tongue, glossitis, stomatitis, pancreatitis, and modification of taste of alcoholic beverages.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Genitourinary</content>
                     <content styleCode="italics">:</content>Overgrowth of
 
  <content styleCode="italics">Candida</content>in the vagina, dyspareunia, decreased libido, proctitis.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Hematopoietic</content>
                     <content styleCode="italics">:</content>Reversible neutropenia, reversible thrombocytopenia.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Hypersensitivity Reactions</content>
                     <content styleCode="italics">:</content>Urticaria; erythematous rash; flushing; nasal congestion; dryness of the mouth, vagina, or vulva; fever; pruritus; fleeting joint pains.

 </paragraph>
                  <paragraph>
                     <content styleCode="italics">Renal</content>
                     <content styleCode="italics">:</content>Dysuria, cystitis, polyuria, incontinence, a sense of pelvic pressure, darkened urine.

 </paragraph>
                  <paragraph>
                     <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Saptalis Pharmaceuticals, LLC. at 1-833-727-8254 or FDA at 1-800-FDA-1088 or
  
   <content styleCode="italics">www.fda.gov/medwatch</content>.
 
  </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250114"/>
            </section>
         </component>
         <component>
            <section ID="ID_643b8874-8e76-4caf-af02-2f18378b558e">
               <id root="2bb2bd7b-1921-1821-e063-6294a90a5c0e"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>There is no human experience with overdosage of metronidazole vaginal gel. Vaginally applied metronidazole gel, 0.75% could be absorbed in sufficient amounts to produce systemic effects. (See
 
  <content styleCode="bold">
                        <linkHtml href="#ID_0912677e-4590-42cc-814c-4f7264e6572f">WARNINGS</linkHtml>
                     </content>.)

 </paragraph>
               </text>
               <effectiveTime value="20220328"/>
            </section>
         </component>
         <component>
            <section ID="ID_8106f08c-f0ef-47e9-bffa-be6282da7fc9">
               <id root="2bb2bd7b-1922-1821-e063-6294a90a5c0e"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The recommended dose is one applicator full of metronidazole vaginal gel (approximately 5 grams containing approximately 37.5 mg of metronidazole) intravaginally once or twice a day for 5 days. For once-a-day dosing, metronidazole vaginal gel should be administered at bedtime.</paragraph>
               </text>
               <effectiveTime value="20220328"/>
            </section>
         </component>
         <component>
            <section ID="ID_ebcd1f4e-fcec-4d43-9108-b54ec63044ca">
               <id root="2bb2bd7b-1923-1821-e063-6294a90a5c0e"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>Metronidazole vaginal gel, 0.75% is a clear colorless to yellow gel with no visible grit or particles, supplied in a 70 g aluminum tube with HDPE cap and packaged with 5 vaginal applicators.</paragraph>
                  <paragraph>The NDC number for the 70 g tube is 71656-067-70.</paragraph>
                  <paragraph>Store at controlled room temperature 15°C to 30°C (59°F to 86°F). Protect from freezing.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Clinical Studies</content>
                  </paragraph>
                  <paragraph>In a randomized, single-blind clinical trial of non-pregnant women with bacterial vaginosis who received metronidazole vaginal gel daily for 5 days, the clinical cure rates for evaluable patients determined at 4 weeks after completion of therapy for the QD and BID regimens were 98/185 (53%) and 109/190 (57%), respectively.</paragraph>
                  <paragraph>Distributed by: 
  <br/>
                     <content styleCode="bold">Saptalis Pharmaceuticals, LLC.</content>
                     <br/>  Hauppauge, NY 11788 
  <br/>
                     <content styleCode="bold">MADE IN USA</content>
                     <br/>  Rev.11/2024-R2

 </paragraph>
               </text>
               <effectiveTime value="20250114"/>
            </section>
         </component>
         <component>
            <section ID="ID_a2d2dfae-fabc-4d6d-b211-44c594c5cf40">
               <id root="2bb2bd7b-1924-1821-e063-6294a90a5c0e"/>
               <code code="59845-8" codeSystem="2.16.840.1.113883.6.1" displayName="INSTRUCTIONS FOR USE SECTION"/>
               <title>Metronidazole Vaginal Gel, 0.75% 
 <br/>  DIRECTIONS FOR USE
</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">1. Filling the applicator</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>Remove cap and puncture metal seal on tube with the pointed tip of cap. (See Figure 1)</item>
                     <item>Screw end of applicator onto tube. (See Figure 2)</item>
                     <item>Slowly squeeze gel out of tube and into applicator. Plunger will stop when the applicator is full. (See Figure 3)</item>
                     <item>Unscrew applicator and replace cap on tube.</item>
                  </list>
                  <renderMultiMedia referencedObject="c9be43ad-a607-40fe-a266-f899e6b39da7"/>
                  <renderMultiMedia referencedObject="a6e8adff-c0b3-4d03-851e-09f5ace969b5"/>
                  <renderMultiMedia referencedObject="ID_6f5e7b73-141e-439a-8d78-cef596752968"/>
                  <paragraph>
                     <content styleCode="bold">2. Inserting the applicator</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>The applicator may be inserted while lying on your back with your knees bent or in any comfortable position.</item>
                     <item>Hold filled applicator by barrel, and gently insert into vagina as far as it will comfortably go. (See Figure 4)</item>
                     <item>Slowly press the plunger until it stops to deposit gel into vagina and then withdraw the applicator.</item>
                  </list>
                  <renderMultiMedia referencedObject="ID_60392085-5fcb-4371-b67d-ca1d116fe88c"/>
                  <paragraph>
                     <content styleCode="bold">3. Care of the applicator</content>
                  </paragraph>
                  <paragraph>If physician prescribes twice-a-day dosing:</paragraph>
                  <list listType="unordered">
                     <item>After use, pull the plunger out of the barrel. (See Figure 5)</item>
                     <item>Wash both plunger and barrel in warm soapy water and rinse thoroughly.</item>
                     <item>To reassemble applicator, gently push plunger back into barrel.</item>
                  </list>
                  <renderMultiMedia referencedObject="ID_5a6e538e-90f0-4614-81e2-ebbd72060ad6"/>
                  <paragraph>
                     <content styleCode="bold">IMPORTANT</content>
                  </paragraph>
                  <paragraph>For once-a-day dosing, apply one applicator full at bedtime. For twice-a-day dosing, apply one applicator full each morning and evening for 5 days, or as directed by physician.</paragraph>
                  <paragraph>
                     <content styleCode="bold">WARNINGS</content>
                  </paragraph>
                  <list listType="unordered">
                     <item>If significant irritation develops from the use of this medication, discontinue use and consult your physician.</item>
                     <item>Do not use during pregnancy except under the supervision of a physician.</item>
                     <item>Keep this and all medications out of reach of children.</item>
                     <item>For vaginal use only. Not for use in the eyes, on the skin or in the mouth.</item>
                  </list>
                  <paragraph>Store at room temperature. Avoid exposure to extreme heat or cold.</paragraph>
                  <paragraph>See end of carton and bottom of tube for lot number and expiration date.</paragraph>
                  <paragraph>Distributed by: 
  <br/>
                     <content styleCode="bold">Saptalis Pharmaceuticals, LLC.</content>
                     <br/>  Hauppauge, NY 11788 
  <br/>
                     <content styleCode="bold">MADE IN USA</content>
                     <br/>  Rev. 11/2024-R3

 </paragraph>
               </text>
               <effectiveTime value="20250114"/>
               <component>
                  <observationMedia ID="c9be43ad-a607-40fe-a266-f899e6b39da7">
                     <text>Figure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="a6e8adff-c0b3-4d03-851e-09f5ace969b5">
                     <text>Figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_6f5e7b73-141e-439a-8d78-cef596752968">
                     <text>Figure 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_60392085-5fcb-4371-b67d-ca1d116fe88c">
                     <text>Figure 4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="ID_5a6e538e-90f0-4614-81e2-ebbd72060ad6">
                     <text>Figure 5</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="figure-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_97d2e559-54aa-4d0e-8592-fb175d15f70e">
               <id root="2bb2bd7b-1925-1821-e063-6294a90a5c0e"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE/LABEL PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Package/Label Display Panel - 70 g Label</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 71656-067-70</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metronidazole Vaginal Gel, 0.75%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR INTRAVAGINAL USE ONLY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NOT FOR OPHTHALMIC, DERMAL, OR ORAL USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Net Wt. 70 g</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="ID_7f730c28-e12b-4cf8-911f-4aad4e08f87c"/>
                     </content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Package/Label Display Panel - 70 g Carton</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NDC 71656-067-70</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Metronidazole Vaginal Gel, 0.75%</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">FOR INTRAVAGINAL USE ONLY</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">NOT FOR OPHTHALMIC, DERMAL, OR ORAL USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Rx Only</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">Net Wt. 70 g</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <renderMultiMedia referencedObject="b7439ac6-cb9b-4b0a-861d-e8985aed5dee"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20250114"/>
               <component>
                  <observationMedia ID="ID_7f730c28-e12b-4cf8-911f-4aad4e08f87c">
                     <text>Metronidazole Vaginal Gel Tube Label</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="tube-70-g.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="b7439ac6-cb9b-4b0a-861d-e8985aed5dee">
                     <text>Metronidazole Vaginal Gel Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="carton-70g.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>